The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

The Hidden Costs Buried in Healthcare Payment Operations

Healthcare organizations chronically underestimate what it costs to move money, according to Healthcare Dive. The reason is structural: the true cost of payment operations does not sit in one place. It is scattered across four separate budgets, which means no single owner or line item ever captures the full number.

That fragmentation hides real spending. Paper checks, manual reconciliation, printing and mailing, staff time chasing exceptions, and the overhead of managing multiple payment channels all get booked in different departments. Added together, the total is far larger than most finance leaders assume when they look at any one budget.

The practical takeaway for operators is to stop evaluating payment costs department by department and start measuring the end-to-end process. Consolidating and automating payments can shrink manual work and errors, but the case for change only becomes visible once the scattered costs are summed. Until leaders add up all four budgets, the savings opportunity stays invisible.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.